Immunochemistry services director joins PharmaNet

Will expand large molecule services at US firm

Chris Beaver has joined PharmaNet Development Group, a US provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, as director of immunochemistry services.

Beaver will lead the immunochemistry team within the firm’s bioanalytical laboratories and expand its large molecule services, including assay development and sample analysis for biomarker, ELISA, radioimmunoassays, immunogenicity and cell-based assays.

PharmaNet has two GLP-compliant bioanalytical laboratories located in Princeton, New Jersey and Quebec City, Canada.

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Sustainability

Free online course introduces fundamentals of SFC

Learn how SFC can improve efficiency and reduce environmental impact
Manufacturing

Thermo Fisher launches general purpose centrifuges with natural refrigerant cooling

New X and S Series models offer high performance with reduced environmental impact
Regulatory

NOAH calls for Veterinary Medicines Agreement amid concerns over Northern Ireland veterinary medicines supply changes

With EU regulations set to apply fully from 1 January 2026, Northern Ireland could see 10-15% of veterinary medicines discontinued. Industry and government are working on mitigation schemes to protect animal health and ensure continued access to essential treatments
Regulatory

Piramal Pharma Solutions’ bioconjugates facility in Grangemouth, UK, receives updated MHRA GMP certificates

These certificates cover all activities conducted in the site’s Helix building, including its supporting warehouse and laboratory areas
Regulatory

UK-US pharma deal removes tariffs and boosts access to innovative medicines

The UK has secured a zero-tariff agreement on pharmaceutical exports to the US, alongside major reforms to accelerate NHS access to new treatments
Research & Development

€2.5m boost for SensABLATE to revolutionise real-time lung cancer treatment

The next-generation AI and photonics system is designed to provide instant intraoperative confirmation during lung cancer ablation and aims to improve precision, reduce repeat procedures and enhance patient outcomes
Subscribe now